Prostate-specific antigen (PSA) is the most useful biochemical parameter in PCa clinical practice [2] with a more limited value at the advanced stage due to increased PCa heterogeneity and de-differentiated lesions, also considering that optimal intervals for PSA follow-up are unknown [3]. This evidence concerns the gene KLK3 and posterior cortical atrophy.